New medications to treat type 2 diabetes by Bereznicki, LRE & Peterson, GM
, evidence- base update
Thearnctee In tme seriesare indepcndcnlly researched and compiled by P~A ccmrrussicneu auloo/:; i:lf'l l}Ij'tlr revreweo.
t
• Have an understanding of the new
classesof medications that are
available ormay soon be available to
treat type 2 diabetes, including their
modesof action, effectiveness and
safety.
• Consider the likelyplace of these
new medications in light of current
therapeutic options for type 2
diabetes.
Learning objectives:
Afterreading thisarticle, the reader
should:
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Introduction
The number of Australians with type 2 diabeteshas tripled
since 1981 and continues to increase. It is projected that
1.6 mill ion Australians will have type 2 diabetes by 2030.'
Effective treatment of hyperglycaemia is a priority, given
that strict glycaemic control reduces the microvascular
complicat ions of type 2 diabetes." Epidemiological
data fr om the UK suggests that improving glycaemic
control wi ll also reduce the risk of macrovascular
complications (e.g. cardiovascular disease),' although
this is controvers ial and it is recognised that improving
glycaemic control is only one of a number of possible
strategies to reduce the macrovascular risk associated
with diabetes. Health professionals involved in the
management of diabetes should focus on blood pressure
management, cholestero l loweri ng and the use of low-
dose aspirin as means of reducing cardiovascu lar risk,
as well as control of blood glucose.' The treatment of
hyperglycaemia in type 2 diabetes is complicated, and
combination hypoglycaemic therapy is often required
to achieve and maintain target blood glucose levels.
Unfortunately, recent Australian data suggests that
target glycated haemoglobin IHbA"llevels are achieved
in only 30-50% of type 2 diabetics who are managed
in the primary care setting.··· The focus of this article
is to review the evidence for the latest medications to
emerge in the battl e to manage hyperglycaemia in type
2 diabetes,
A range of options
The pathogenesis of diabetes has been traditiona lly
characterised by absolute or relative lossof pancreatic B cell
function and insulin deficiency or tissue resistance' More
recently, it has become clear that addit ional pancreatic and
gut hormones play an important role in glucose homeostasis.
These hormones nowprovide additional therapeutic targets for
medications to treat hyperglycaemia associatedwith diabetes.
Table 1 li sts the main characteristics of medication classes
that are or may soon be available to treat type 2 diabetes.
TheFood and DrugAdministration IFDAI approved the incretin
mimetic exenatide in the US in 2005. l ast year exenatide
gained approva l in Australia as adjunctive therapy for patients
who have not achieved adequate glycaemic control with
metformin. a sulfonylurea. or both. Pramlintide, an injectable
synthetic hormone that resembles human amylin, was also
approved by the FDA in 2005. In 2006, the FDA approved the
first oral incretin enhancer, sitagliptin, for use as monotherapy
or in combination with metformin or a thiazolidinedione for
type 2 diabetes . Sitagliptin IJanuvial was registered by the
Therapeutic Goods Administration as a combination therapy
with metformin, a sulfonylurea or a thiazolidedione in
December 2007. The first inhaled insulin to market, Exubete,
was withdrawn from the US marke t in October 2007 due to
poor sales. However, other inhaled insulin produc ts are in the
\"boo 271 Nunncr 3 1MarCh 2OC6
advancedstage of clinical trials andare likely to beapproved
In the US In the near future.
Incretin therapy
The incretin effect is the augmentat ion of glucose-stim l t d
. I' . ua e
msu In se~retlOn by intestinally derived peptides. which are
released In the presence of glucose in the gastrointestinal
t ract." This theory is based on the observation that an oral
dose of glucose causes more insulin secretion than the same
amount given intravenously. Improved understanding of this
effect hasled to the development of newantidiabetic agents.
The incretin effect results primari ly from the actions of two
peptides, glucose-dependent insu linotropic polypeptide IGIP}
and glucagonlike peptide 1 IGlP-11." lncretins are rapidly
inactivated by the enzyme dipeptidyl peptidase 4 IDPP4l,
result ing in a short halt-lite.'? The action of this pathway
appear to be diminished in type 2 diabetes, making the
pathway a target for novel pharmacologic agents." GlP-1, in
addition to potentiating glucose stimulated insulin secretion,
also inhibits glucagon secretion, retards gastric emptying
and reduces appetite. In animal studies, GlP-1 stimulates
prolif eration of ~ cells and inhibits their apoptosis," an
encouraging finding that is yet to be confirmed in human
studies.
Incretin mimetics: GLP-1 analogues
Exenat ide was the first incretin mimetic resistant to DPP4
degradation approved bythe FDA." Unlike GlP-1 , exenatide is
not rapidly inactivated, allowing it to be administered twice-
daily. Exenatide is administered by subcutaneous injection
before the morning and evening meals. However, a once-
weeklyadministered lonq-actinq formulation of exenatide has
recently been tested." l irag lutide, another Gl P-l analogue,
may be administered once daily. It is likely that the FDA will
consider approving this product in 2008.
A systematic review and meta-analysis of GlP-1 analogues
lexenatide and liraglutide} was conducted recently." It
included eight published trials In = 3,1 39 adult participants}
in which a GlP-1 analogue was used for type 2 diabetes.
GLP-1 analogues were added to existing inadequate therapy
Ilifestyle or oral hypoglycaemics} and compared with a
double-blind, injectable placebo. metformin. or open-label
subcutaneous insulin Iglargine or biphasic aspartl.' Another
small study In = 45) was included in which a lonq-actinq
formulation of exenatide was compared to placebo in patients
taking metformin. The duration of GlP-l analogueuse in these
studies ranged from 15 to 52 weeks. Glp ·1 analogue therapy
resulted in a statistically significant reduct ion in HbA" from
baseline compared to placebo (weighted mean difference
-0.97%,95% confidence interval lell -1.1 3% to ·081%). In
open-label studies comparing exenatide with subcutaneous
insulin there was no difference in HbA" . Patients receiving
exenatide were more likely to achieve target HbA" levels
.... : . ~~ .
,,-evidence- base update
111e arucles III Illi~ series ale Ilidependently rr.sl1a rclled and compiled bl' PSA commissioned authors and pe~ r reviewed.
Table 1. Characteristics of currently avai lable blood glucose lowering medications (modified from Heine et al. 2006)l3
Medication(sl Delivery Reduction Main mode of action Benefits Side effects and limitations
in HbA!C
(%)
Metforrnin Om l 1.5 Lowers production of hepat ic No weight qain; Gastro intestinal complaints: lactic i
qlucnse cheap acidosis (very rare)
Sulfonylureas Oral 1.5 Stimulates insulin secretion Cheap Hypoglycaemia; weight gain
(gibenclamide,
glimepiride,
gliclazide. glipizide)
Thiazolirlinediones Oral 05 -1.5 Improve insulin sensitivity Increases HDL Fluid retention, which may lead
(pioglitazone, levels to heart fa ilure; weight gain:
rosiqlitazone] increased risk of CVD; expensive
~ - g l u co s i d a se Oral 0.5-0.8 Retard intestinal absorption of No weight gain Gastrointestinal side effects;
inhihitors qlucoss mu lti ple daily dosing required;
(acarbose) expansive: low potency
Meglitinides Oral 1-1.5 Stimulate insulin secretion Short-acting; Need to be taken at meal time;
(repaglinidel less risk of expensive
hypoglycaemia
Dipeptirlyl Oral 0.6-0.9 Stimulate insulin secretion Low risk of Limited experience; expensive
peptidase-a (DPP-4) hypoglycaemia
inhibitors"
Glucagon- Subcutaneous 0.8-1.1 Stimulates insulin secretion; Weight loss Need to be injected;
like peptide-l injection suppressesglucagon: retards gastrointestinal side effects:
analogues gastric emptying andreduces limited experience: expensive
(exr.natide) energy intake
Pramlintide Subcutaneous 0.5-1 .0 Retards gastric emptying and Weight loss Needs to be injected before meals;
injection reduces energy intake gastrointestinaI side-effects;
expensive; experience limited
Subcutaneous Subcutaneous > 2 Stimulatesperipheral glucose Reduces severe Weight gain; hypoglycaemia;
insulin injection uptake and inhibits glucose hyperglycaernia; needs to be injected: monitoring
output cheap; extensive requirements
experience
Inhaled insulin" Inhaled 0.5-1.0 Stimulates peripheral glucose No injecti ons Multiple daily dosing; monitoring
uptake andinhibits glucose required requirements; lOlly term pulmonary
output effects unknown; expensive and
experience limited
"Not curren tly approved for use in Australia.
compared to those taking placebo (45% versus 10%.
respective ly). but there was no difference between exenatide
and insulin in comparative studies. Exenatide was superior to
insu lin at reducing postprandial glycaemia. while there was
no difference in fasting plasma glucose. One key advantage of
the GLP-1 analogues comparedto their comparators is weight
loss (weighted meandifference -2.37 kg; 95% CI -3.95 to -0.78
kg). Weight loss was more pronounced when exenatide was
compared to insulin (weighted mean difference -4.76 kg; 95%
CI -6.03 to -3.49 kg ) than with other agents. Weight loss was
progressive. rlose dependentand did not appear to plateau at
week 30.
Severe ilypoglycaemia (requiring intervention) was rare with
GLP-1 analogues and has only been reported in patients also
receiving sulfonylureas. The riskof hypoglycaemia wassimilar
between exenat ide and insulin (approximately 2% in each
group), Nausea and vomiting were themost commonly reported
adverse events with exenatide compared to a comparator.
with nausea and vom iting occurring in up to 57% and 17%
of pa tients treated with exenatide. respect ively. Nausea was
most common early in the course of therapy and declined
thereafter. In the comparative study with insulin glargine. 19%
of patients using exenatidedropped out of the trial. compared
to 10% of patients using the insulin." Gastrointostinal adverse
reactions were common and contributed to these withdrawals.
Diarrhoea was also more common in patients receiving
GLP- l analogue therapy. Exenatide therapy commonly (in up
to 67% of patients) results in the formation of antibodies to
the molecule. as it is not identical to human GLP-1 . However,
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this has not been associated with ilny effect on outcomes or
adverse events." It is recommended thatexenatide is initiated
at a dosage of 5mcg twice-da ily to improve tolerability and
increased to a maximum dosage of 1mcg twice-dai ly."
Incretin enhancers: DPP4 inhibitors
(the 'gliptins')
Given that GLP-1 analogoes require injection, cons iderable
effort has been made to develop oral agents that target the
incretin pathway. Inhibition of DPP4 extends the half-life
of native incretins. prolong ing their action." A systematic
review and meta-analysis of DPP4 inhibitions lsitagliptin and
vildagliptinl was cond ucted recsntlv." DPP4 treatment was
compared to placebo as monotherapy or as add-on therapy to
oral hypoglycaemic agents or insulin in 13 randorn ised trials
(n = 4,780). The durat ion of these trials ranqed from 12 to 52
weeks. The incretin enhancers lowered HbA1t compared with
placebo with similar effectiveness as monotherapyor as add-
on therapy (weighted mean difference -0.74%; 95% CI -0.85%
to -0.62%l. Sitagliptin and vildagliptin have not been direc tly
compared, but seem to be similarly effec tive in lowering HbA't
compared to placebo , In four trials (n = 3,053) comparing
a DPP4 inhibitor to other hypog lycaemic agents (glipizide,
metformin or a thiazolidenedioneL the DPP4 inhibitors were
slightly less effective at lowering HbA1, (weighted mean
difference -0.21%; 95% CI 0.02% to 0.39%). Patients trea ted
with DPP4 inhibitors were more likely to ach ieve target HbA1t
levels compared to placebo (43% versus 17%, respectively).
Compared to placebo, DPP4 inhibitors were associated with
a small increase in weight (weighted mean difference 0.5 kg;
95% CI 0.3 to 0.7 kg). Th is was main ly because meLformin
was assoc iated with an average 2.2 kg weight loss compared
to vildag liptin. However, sitagliptin and vildag liptin were
associated with weight loss compared to glipizide and
thiazolidenediones, respectively. Severe hypoglycaemia was
rare with GPP4 inhibitors, and there was no difference in
the incidence of mild to moderate hypog lycaemia between
GPP4 inhibitors and comparators, DPP4 inhibitors were well
tolerated, with no increased risk of gastrointestinal adverse
effects (nausea, vomiting, abdominal pain and diarrhoeal.
Adverse effects noted significan tly more frequently with DPP4
inhibitors compared to comparators included nasopharyngitis,
urinary tract infection and headac he."
Amylin analogue: pramlintide
Amylin is produced by the ~ cells of the pancreas and is
secreted together with insulin in response to meals. Its ro le
is to complement the action of insulin by regulating the
rate of glucose entry into the circulation following a mea l."
It achieves this by slowing gastric emptying, suppress ing
inappropriate postpra ndial glucagon secretion and regulating
food intake." Amylin concentrations are deficient in patients
with type 1 diabetes who are also de ficient in insulin." Native
amyl in exhibits poor solubility and a tendency to aggregate,
Pharmacist
and is not su itable for clinical use. Pramlintide is a synthetic,
soluble ana logue of amylin with similar mechan ism s of action
that raqulata the appearanc e of glucose in the circulation
following meals." In the US, pramlintide is indicated as
an adjunct to mealtime insulin in patients with type 1 and
2 diabetes. In clinical studies, pramlintide improved post-
prandial glucose control when added to insu lin therapy in
people with type 1 or 2 diabetes and was also associated
with weight loss." In people with type 2 diabetes who require
insulin therapy, pram lintide therapy has been shown to reduce
HbA1c and body weiqht." In one 52 week study. patients
treated with pram lintide (75 or 150mcg tds) had a reduction
of HbA
't of 1% compared to 0.5% IP < 0.01) for the placeboqroup." Additionally, patients in each of the pramlint ide
dosage groups had significant decreases in mean body weight
compared to placebo. Other studies have reported similar
results in type 2 diabetics treated with a range of doses of
pramlintide (60mcg tds, 90mcg tds or 120 mcg bd).2011Nausea
was more than twice as likely in patients treated with
pramlintide than with placebo in these studies, although it did
not increa se drop-out rates. In peop le with type 1 diabetes,
pra rn lintide reduced insulin requirements by 7-8%, without
increasing the risk of hypoglycaemia compared to placebo."
In the majority of studies, pramlintide was administered
by injection, 15 minutes prior to meals and sepa rated from
the insu lin injection. However, some smaller studies have
demonstra ted that combining insu lin and pramlintide in the
same injection does not attenuate the therapeutic effects of
pramlintide."
Inhaled insulin
The major drawback to traditiona l insulin therapy is its need
for injection. This has led to attempts to develop a su itable
alternative that can be administered by a more desirable
route for diabetic .patients. Pharmacokinetic studies have
demonstrated that inhaled insu lin is similar to the rapid-onset
insu lin analogues (Iispro and aspart) but possesses a slightly
longer duration of action." It is therefore regarded as a
rapid -acting insul in and is suitable for control of postprandial
hyperglycaemia. Inhaled insulin has been compared with
subcutaneous insulin regimens in patients with type 1 and
type 2 diabetes, and with ora l hypoglycaemics in those with
type 2 diabetes." The combination of inhaled insu lin, taken
before each mea l, and ultralente at night resulted in similar
glycaemic control as a combination of lente and regular insulin
two to three times daily among patients with type 1 and type
2 diabetes. Patients receiving the inhaled insu lin regimen
had slightly lower ra tes of hypoglycaemia.26,2' In people with
type 2 diabetes, the addition of inhaled insulin to existing
ora l therapywas shown to be more effective over 3-6 mun hs
than adding a second oral hypoglycaemic medication. H Inhaled
insulin, however, is consistently associated with a higher
risk of hypog lyca emia than is associated with oral aqents."
In clinica l trials, patien ts were gen era lly more satisfied with
inhaled insulin than with subcutaneous insulinz617.29
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Unfortunately, at present, inhaled insulin therapy is limited by
a number of drawbacks. These include expense, the potential
for a reversible decline in lung function associated with its
use, a theoretical risk of formation Dr promotion of cancer with
chronic use and tho possibility that practical issues such as
smokinqand the presence ot upper respiratory tract infections
may affect the degree of insulin absorption and the risk of
hypo- or hyperglycaemia ,. It is also short-actinq and would
not replace the need fora basal insolin. Inhaled insulin is more
suitable for patients with HbA" levels that remain elevated
after fastingqlucose levels have been controllsc with a basal
insulin.
The tachnoloqv required for the adm inistrat ion ot inhaled
insulin is also more demanding than for other inhaled
med ications, where such a high degree of precision in dosing
is not required. In the case of Exubera, this resulted in
difficulties in dosing, The dosage of Exubera was measured
10 milligrams, not units, andinitial dosingwas based on body
weight rather than thecarbohydrate content of meals. Most of
the devices required to inhale insulin are relatively large and
awkward, requiring time and skill to master, although theywill
hopa fullv improve with furtherdevelopment."
Place of newer agents in the treatment of
type 2 diabetes
A recent systematic review provides some evidence on the
relative safety and effectiveness of older oral medications
(metformin and sulfonvlureas ] in comparison with newer
oral agents (thiazolidinediDnes, n-qlucosidase inhibitors and
meqlitinides]." The review round that compared with the
newer, more expensiveagents, older medications have simi lar
or superiDr effects on glycaemic control. lipids and other
intermediate endpoints. This findingsupports the status Df the
newer agents as add-on therapy to metformin, a sulfonylurea
or both in type 2 diabetes."
The roles Df exenatide and sitagliptin in the treatment of
type 2 diabetes are unclear. At present, if opt imum therapy
with oral hypoglycaemics dDes not cDntrol the disease,
subcutaneDus insulin is the next step." Exenatide may have
similar effects on HbA" to insuliu glargine," or twice-daily
insulin aspart," but it causes more adverse effects. The ideal
patient for whDm exenatide could be considered is obese,
with elevated glucoseconcentrations in spite of therapy with
oral hypoglycaemics" The effects of pramlintide on blood
glucose and body weight are more modest compared with
those of exenatide. Pramlintide may have a greater role in type
2 diabetic patients who have longstanding disease and are
more insulin·deficient. as exenatide requires ~ cell function
to ach ieve its therapeutic actiolls, whereas pramlintide does
not." It is likely that the practica l drawbacks associated
with inha led insulin will be overcome in time, but they are
signif ica nt at present. This is perhaps most evident in the
decision tDremove the first inhaled insulin from the market
_me 27 I t>I.rnt€r aIMatcn =
ill the US recently due to poorsales. Newly developed inhaled
insu lin products may prove more succossful. The new classes
of hypoglycaemic agents will need continuod evaluation in
terms of long-term efficacy and safety to fully determine their
role among thewell-established therapies for type 2 diabetes.
Dr LukeBer91nicki and Prutessor Gregory Peterson. Unit for Medication
Outcomes Besearch and Education.School of Pharmacy. Un iversity of Tasmania.
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